Innate Pharma Adr stock is traded at $1.59, with a volume of 7,572. It is up +3.25% in the last 24 hours and up +7.43% over the past month. Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
Previous Close:
$1.54
Open:
$1.54
24h Volume:
7,572
Relative Volume:
0.40
Market Cap:
$177.60M
Revenue:
$3.13M
Net Income/Loss:
-$55.77M
P/E Ratio:
-
EPS:
-$0.6145
Net Cash Flow:
-$61.24M
1W Performance:
+13.57%
1M Performance:
+7.43%
6M Performance:
+16.91%
1Y Performance:
-17.19%
1-Day Range:
$1.53$1.61
1-Week Range:
$1.40$1.61
52-Week Range:
$1.17$2.71
Innate Pharma Adr Stock (IPHA) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS